The study of feasibility and effectiveness of enhanced laser vapolization and coagulation(ELVC)using indocyanine green(ICG) solution and Diode laser for benigin prostatic hyperplasia(BPH):A phase 2 Trial

The study of feasibility and effectiveness of enhanced laser vapolization and coagulation(ELVC)using indocyanine green(ICG) solution and Diode laser for benigin prostatic hyperplasia(BPH):A phase 2 Trial - ELVC for BPH

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002230

Enrollment

Registered

2009-08-01

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH

Interventions

ELVC therapy as a primary treatment

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.BPH;prostatic volume more than 50cc, amount of residual urine more than 50cc 2.written informed consent

Exclusion criteria

Exclusion criteria: 1.Prostatic cancer 2.Patients with serious comobidities;serious cardiac complications such as uncontrollable angaina,myocardal infaraction within 3 months,heart failure,arrythemia required treatment,uncontrollable daibetes mellitus and hypertion

Design outcomes

Primary

Measure	Time frame
6 months after the treatment	—

Secondary

Measure	Time frame
IPSS,the prostatic volume,flow study,QOL at 2,4 weeks and 3,6 months after the treatment	—

Countries

Japan

Contacts

Public ContactShigehiro Kubota

Kanda Ishin Clinic Department of Urology

postmaster@ishin-kai.or.jp03-5833-3240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026